

Progress in Allergy

Vol. 15

Progress in Allergy

Vol. 15

Editors

PAUL KALLÓS, Helsingborg; BYRON H. WAKSMAN, New Haven, Conn.
and A. DE WECK, Bern

Contributors

F. CELADA, Stockholm, W. L. ELKINS, Philadelphia, Pa., S. K. SINGHAL,
London, Ont., G. F. SPRINGER, Evanston, Ill., T. L. VISCHER, Basel,
G. A. VOISIN, Paris, H. WIGZELL, Stockholm

33 figures and 40 tables



S. Karger · Basel · München · Paris · London · New York · Sydney 1971

Progress in Allergy

- Vol. 1:* 400 p., 38 fig., 1939 (first edition)
XXIV + 400 p., 38 fig., 1966 (second edition)
Vol. 2: VIII + 356 p., 50 fig., 37 tab., 1949
Vol. 3: VIII + 572 p., 82 fig., 61 tab., 1 cpl., 1952
Vol. 4: VIII + 520 p., 149 fig., 63 tab., 1954
Vol. 5: XI + 508 p., 103 fig., 6 tab., 1958
Vol. 6: XII + 600 p., 78 fig., 38 tab., 1962
Vol. 7: XII + 334 p., 46 fig., 42 tab., 1963
Vol. 8: X + 261 p., 35 fig., 32 tab., 1964
Vol. 9: VIII + 308 p., 45 fig., 9 tab., 1965
Vol. 10: XII + 292 p., 16 fig., 14 tab., 1967
Vol. 11: XX + 184 p., 40 fig., 21 tab., 1967
Vol. 12: XIV + 317 p., 27 fig., 12 tab., 1968
Vol. 13: XXII + 429 p., 51 fig., 16 tab., 1969
Vol. 14: XVI + 340 p., 35 fig., 18 tab., 1970

S. Karger · Basel · München · Paris · London · New York · Sydney
Arnold-Böcklin-Strasse 25, CH-4000 Basel 11 (Switzerland)

All rights, including that of translation into other languages, reserved.
Photomechanic reproduction (photocopy, microcopy) of this book or parts thereof
without special permission of the publishers is prohibited.

© Copyright 1971 by S. Karger AG, Verlag für Medizin und Naturwissenschaften, Basel.
Printed in Switzerland by Schellenberg-Druck, 8330 Pfäffikon ZH

Contents

<i>Introduction</i>	
A. DE WECK (Bern)	1
 <i>Blood-Group and Forssman Antigenic Determinants Shared between Microbes and Mammalian Cells</i>	9
G. F. SPRINGER (Evanston, Ill.)	
 I. Introduction	10
II. Discovery and Serological Properties of Heterophile Antigens	12
III. Heterophile Antigens of Bacteria	13
A. Forssman-Like Antigens	13
B. 'Human Antigen' of <i>Shigella shigae</i>	15
C. <i>Pneumococcus</i> Type XIV Heterophile Antigen	16
D. Blood-Group ABH(0) Active Antigens in Gram-Negative Bacteria	17
IV. Blood-Group ABH(0) Active Substances and Forssman Antigen in Viruses	24
V. Blood-Group P-Like Substances in Lower Forms of Life	27
VI. Specific Inhibition of Blood-Group Antibodies by Substances Isolated from Higher Plants and Molds	28
VII. Biological Implications of Sharing of Antigenic Determinants between Microbes and Mammalian Cells	29
A. Origin of Human Blood-Group Isoantibodies A and B	30
B. Relation of Blood-Group ABH(0)- and Forssman-Specific Determinants of Microbes to Disease	33
I. Importance of Heterophile Antigens and Antibodies in Possible Prophylactic and Curative Treatment	33
2. Noxious Effects of Microbe-Induced Forssman and Blood-Group Antibodies	37
3. Endemic and Epidemic Diseases and Blood-Group Active Microbes	42

VIII. Chemistry of the Forssman and Blood-Group Cross-Reacting Antigens and their Immunodeterminant Structures	44
A. Forssman Antigens	44
1. Mammals	44
2. Bacteria	46
a) <i>Shigella</i>	46
b) <i>Pneumococcus</i>	47
B. Structures Responsible for Cross-Reactivity with Horse Anti <i>Pneumococcus</i> Type XIV Serum	48
C. Cross-Reactivity with the Human Blood-Group ABH(0) Specific Determinants	50
D. Blood-Group Active Substances from Higher Plants and Molds	56
IX. Blood-Group and Forssman-Active Antigens in Transplantation	56
X. Heterogenetic Infectious Mononucleosis Receptors	58
XI. Concluding Remarks	61
References	62

Cellular Immunology and the Pathogenesis of Graft Versus Host Reactions 78
W. L. ELKINS (Philadelphia, Pa.)

I. Introduction	81
II. The Basic Prerequisites of GVHR	81
III. Survey and Critique of Current Methodology	82
A. Measurements at the Syndrome Level	82
B. The Simonsen Assay	82
C. Assay of Phagocytic Activity of the Reticulo-Endothelial System	83
D. Enumeration of Focal Periportal Infiltrates	83
E. Local GVHR	84
F. Measurement of Proliferation of Donor Cells in a Local GVHR	86
G. Measurement of Proliferation of Donor Cells During a Systemic GVHR	88
H. The Production of Focal Lesions on the Chorio-Allantoic Membrane of the Chick Embryo	88
I. <i>In vitro</i> Analogues of the GVHR	89
J. Summary	90
IV. The Antigens which Elicit GVHR	91
A. The Dominant Histocompatibility Locus of a Species	91
1. Experimental Identification of the Relevant Antigens	91
2. The Importance of the H1-A Antigens in Human GVHD	93
B. GVHRs Elicited by H-Antigens of Minor Loci	96
C. The Elicitation of GVHR Across Species Barriers	97
D. Summary	99
V. The Cells which Initiate GVHR	99
A. The Ontogeny of the Reactive Cells	100

1. Precursors of H-ARC in Hematopoietic Tissues and the Thymus . . .	100
2. Thymus Dependent Maturation of H-ARC	102
3. GVH Disease in Thymectomized Hosts	104
4. The Question of H-ARC which are not Thymus Dependent	104
5. Possible Role of Occult Sensitization in the Ontogeny of H-ARC . .	105
B. Morphology, Distribution, and Life Span of the Initiating Cells	106
1. Lymphocytes	106
2. Other Cell Types: Macrophages and Hematopoietic Stem Cells . . .	107
C. Specific Suppression of Host Reactive Lymphocytes by Prior Induction of Immunologic Tolerance in the Donor	108
D. Sensitivity of H-ARC to Antilymphocyte Serum	109
E. Sensitivity of H-ARC to Irradiation, Antiproliferative Drugs, and Adreno- cortical Steroids	109
F. Summary	110
VI. Effects of Prior Immunization of the Donor Upon the Cells which Initiate GVHR	111
A. Effects of Donor Sensitization on Local Cutaneous GVHR	112
B. Effects of Donor Sensitization on Systemic GVHR	112
C. Effects of Donor Sensitization on Yield of CAM Pocks	113
D. Effects of Sensitization on the Proliferative Response of Donor Cells . . .	113
E. Hyperacute GVH Disease Mediated by Immune Macrophages	114
F. Summary	115
VII. Clonal Selection of H-ARC	115
A. Donor Sensitization Experiments and Clonal Selection Theory	116
B. Competition of Antigens in GVHR	116
C. Frequency of Cells which Respond to a Single Strong H-Antigen	117
D. Summary	119
VIII. The Establishment, Localization and Activities of the Donor Cells which Re- act Against the Host	119
A. Establishment of Donor Cells in the Host	119
B. Localization of the Reacting Donor Cells	120
C. Proliferation of Donor Lymphocytes	121
1. Chromosome Marker Studies and their Pitfalls	122
2. Antigen Dependent Donor Cell Proliferation in the Pathogenesis of GVHR	126
3. Evidence that Donor Cell Proliferation is Non-Essential in the Patho- genesis of GVHR	127
D. Development of Hepatic Macrophages from Donor Lymphocytes During a GVHR	128
E. Tissue Injury Mediated by Immunologically Activated Donor Cells in GVHR	129
1. Contact Dependent Cytotoxic Effect of Committed Lymphocytes on Antigenic Target Cells	129
2. Tissue Damage Mediated by 'Non-Specific' Cytotoxic Factors	130
3. Synthesis of Antibodies by the Reacting Donor Cells	131
F. Summary	131

IX. Interactions of Lymphocytes and Allogeneic Cells of Hematopoietic Origin in Transplantation Immunology	132
A. The Immunogenic Stimulus in Renal and Cutaneous GVHR	132
B. The Continuing Requirement for Immunogenic Leukocytes in the GVHR	134
C. The Importance of these Mixed Cell Interactions in the Pathogenesis of GVHD	135
D. Possible Importance of 'Passenger' Leukocytes as Immunogenic Agents in Allograft Rejection	136
E. Summary	137
X. The Finite Duration of GVHR	137
A. The Field Phenomenon	139
B. The Host Becomes Non-Immunogenic	140
C. Induction of a Countervailing Host Versus Graft Reaction	141
1. Conventional Graft Rejection	141
2. Genetic Tolerance, Hybrid Resistance, and Allogeneic Inhibition	141
D. The Possible Role of Blocking Antibodies	143
E. The Inhibitory Effects of Host Antigens on the Donor Cells	144
1. The Acquisition of Specific Tolerance by the Grafted Population of Competent Lymphocytes	144
2. The Acquisition of Specific Tolerance by the Lymphocyte Population Derived in the Host from Hematopoietic Precursors of Donor Origin	145
3. The Hypothesis of 'Allergic Cell Death'	146
F. Differentiation and Senescence of the Reacting Cells	147
G. Summary	147
XI. The Effects of the GVHR Upon the Host	148
A. The Inflammatory Response of the Host to the GVHR	148
B. The Effects of the GVHR Upon the Immunologic Responsiveness of the Host	150
1. Depressed Immunologic Function	150
2. Enhanced Immunologic Function	151
C. Lymphoid Atrophy	156
1. Development of Lymphopenia in Systemic and Local GVHR	156
2. The Etiology of Lymphoid Atrophy	157
3. Pathogenic Effects of Lymphoid Atrophy	157
D. Anemia and Other Blood Dyscrasias	158
E. Epithelial Lesions in GVHD	159
F. Other Lesions of GVHD	160
G. The Late Complications of GVHD	162
H. GVHD in Man: A Question of Diagnosis	162
I. Summary	164
XII. Epilogue	164
References	167

<i>Cognition and Recognition of Antigen by Cell Associated Receptors</i>	188
S. K. SINGHAL (London, Ont.) and H. WIGZELL (Stockholm)	
I. Introduction	188
II. Surface Immunoglobulin: Presence and Production by Lymphocytes	190
III. Localization and Production of Cell-Bound, Antigen-Combining Receptors	192
IV. Antigenic Similarities between the Humoral Immunoglobulin Molecule and the Cell Surface Receptor for Antigen	195
V. Binding Characteristics of 'IgM' and 'IgG' Surface Receptors	199
VI. Indirect Evidence of Cell-bound Receptors as Regulators of the Immune Response <i>in vivo</i>	202
VII. Analysis of the Avidity of the Antigen-Combining Surface Receptors Using <i>in vitro</i> Methods	204
VIII. Specificity and Size of the Antigen-Combining Area of the Surface Receptors	206
A. The Binding Capacity for Isolated Haptenic Groups	206
B. The Binding Capacity for Complex Macromolecules (Carriers)	207
IX. On the Number of Antigen-Combining Receptors per Unit Surface Area	211
X. Summary	212
Acknowledgements	214
References	215
 <i>The Cellular Basis of Immunologic Memory</i>	 223
F. CELADA (Stockholm)	
I. Introduction	224
A. Positive Memory and Negative Memory	224
B. Interplay with Mental Memory	225
C. Memory in Various Immune Responses and Limited Scope of the Present Article	226
II. Antigen and the Regulation of Memory	227
A. Priming	227
B. Persistence	229
C. Processing	229
D. Elicitation of Secondary Response	230
III. Nonspecific Interference with Memory	232
A. Physical	233
B. Chemical	234
C. Serological	235
IV. Memory for Humoral Responses of Different Immunoglobulin Class and in Cell Mediated Immunity	235
V. Decay of Memory	238

Contents	X
VI. Cytology and Histology	240
VII. Specificity	242
A. Antigen Specificity	242
1. Possibility of Eliciting Anamnestic Response by Non-Specific Substances	242
2. The Role of Carrier in Hapten Immunogenicity	242
3. The 'Predominant' Role of a Given Antigen Specificity for Secondary Response and Tolerance Induction Towards Another Determinant of the Same Molecule	242
4. Possible Role of Antibody in Determining 'Carrier' Function.	243
5. Original Antigenic Sin	243
B. Specificity of Antibodies	245
C. Specificity at the Cellular Level	246
VIII. Avidity and Affinity	247
IX. Existing Models and Hints of Higher Complexity	249
X. Evidence for Cooperation: Which is the Memory Cell?	251
A. Evidence Suggesting that Class, Allotype and Antigen-Binding Specificity are Determined by the AFCP	253
B. Data Suggesting that Specific Information is Carried by the 'Thymus-Dependent' Cells.	254
XI. Conclusion	255
Acknowledgements	257
References	258
 <i>Immunologic Aspects of Chronic Hepatitis</i>	 268
T. L. VISCHER (Basel)	
1. Introduction	269
2. Definition of Chronic Hepatitis	270
2.1. Chronic Persistent Hepatitis	270
2.2. Nonspecific Reactive Hepatitis	271
2.3. Chronic Aggressive Hepatitis	271
2.4. Primary Biliary Cirrhosis	274
3. Evidence for Disturbed Immune Mechanisms	274
3.1. Histological Findings	274
3.2. Hypergammaglobulinemia	275
3.3. Autoantibodies	276
3.3.1. Complement Fixing, Non-Liver-Specific Antibodies	277
3.3.2. Rheumatoid Factors	277
3.3.3. Antinuclear Factors	277
3.3.4. Mitochondrial Antibodies	277
3.3.5. Smooth Muscle Antibodies.	278
3.3.6. Sex Distribution and Epidemiology	279
3.4. Relationship of Chronic Hepatitis to Other 'Immune Diseases'	280

3.5. Therapeutic Results with Immunosuppressive Drugs	282
3.5.1. Steroids	282
3.5.2. 6-Mercaptopurine and Azathioprine	282
3.5.3. The Liver in Patients Treated with High Dosage of Immunosuppressive Drugs	283
3.6. Lymphocyte Cultures in Acute and Chronic Hepatitis	284
3.7. The Leucocyte Migration Test in Chronic Hepatitis	285
3.8. Immune Capacity of Patients with Chronic Liver Diseases	285
3.8.1. Antibody Production	285
3.8.2. Delayed Hypersensitivity	285
4. The Liver in Immune Reactions	285
4.1. The Liver and Immunization	286
4.2. Consequences of Liver Damage on Immune Reactions	286
5. Attempts to Produce Chronic Hepatitis in Animals	287
5.1. Transplantation Reactions	287
5.1.1. Graft-versus-Host Reaction	287
5.1.2. Unmodified Liver Allograft Rejection	288
5.2. Antigen-Antibody Complexes	288
5.3. Liver Antisera	289
5.4. Organ-Specific Immunization Procedures	289
5.4.1. Immunization with Whole Organ Extracts	289
5.4.2. Immunization with Liver-Specific Antigens	290
6. Viral Agents in Acute and Chronic Hepatitis	290
6.1. Viral Agents in Acute Hepatitis	291
6.2. Viral Agents in Chronic Hepatitis	292
6.3. Hepatitis-Associated Antigen	292
6.3.1. Characterization and General Remarks	293
6.3.2. HAA in Acute Hepatitis	294
6.3.3. HAA in Chronic Hepatitis	295
6.3.4. HAA in Tissues	296
6.3.5. Antigens in Infectious Hepatitis	297
7. Viral Models of Chronic Inflammation	297
7.1. Cytopathic Viruses	299
7.1.1. Canine Hepatitis Virus Infection in the Dog	299
7.1.2. Reovirus-3 Infection	300
7.2. Persistent Virus Infection	300
7.2.1. Infection with the Virus of Lymphocytic Choriomeningitis in Mice	301
7.2.2. The Disease of NZB Mice and Related Strains	302
8. Chronic Hepatitis, Histological Entities with Multiple Pathogenic Pathways	304
8.1. Chronic Persistent and Chronic Aggressive Hepatitis	305
8.2. Chronic Active Hepatitis	308
8.3. Non-Specific Reactive Hepatitis	308
8.4. Primary Biliary Cirrhosis	309
9. Concluding Remarks	309
Acknowledgements	311
References	311

Immunological Facilitation, a Broadening of the Concept of the Enhancement

<i>Phenomenon</i>	328
G. A. VOISIN (Paris)	

Introduction	332
I. History	333
1. Discovery of the Phenomenon	333
2. Early Analysis	333
3. Modern Analysis	334
4. Recent Developments	335
II. Enhancement of Transplanted Tumors: the Classical Phenomenon	336
A. Classical Results on Allografted Tumors	336
1. Description of the Phenomenon	337
(a) Active Enhancement	337
(b) Passive Enhancement	338
(c) Adoptive Enhancement	339
(d) Coexistence of E-F and RR	340
2. Factors of Variation	342
(a) Immunization Procedure	342
(b) Immune Serum	345
(c) Grafted Tumor	348
(d) Recipient	350
(e) Immunogenetic Relation between Donor and Recipient Strains	351
B. Extension to Non-Allografted Tumors	352
1. Heterotransplanted Tumors	352
2. Isotransplanted Tumors	353
3. Tumor-Specific Antigens	354
(a) Chemically Induced Tumors	355
(b) Virus-Induced Tumors	355
C. Summary and Conclusions of Section II	355
III. The Enhancement Phenomenon Outside of Tumors: Immunological Facilitation	355
A. Graft-versus-Host Reactions	356
1. Protection of Newborn Mice against Runt Disease by Passive E-F	357
2. Protection of Newborn Mice against Runt Disease by Active E-F	358
3. Protection of Adult Hybrids against Homologous Disease by Passive E-F	359
4. Protection of Adult Hybrids against Homologous Disease by Active E-F	360
5. Conclusions Concerning the Role of E-F in GVH Reactions	360
B. Non-Neoplastic Allografted Tissues	362
1. Allografted Skin	363
(a) Active E-F	363
(b) Passive E-F	364
2. Ovarian and Endocrine Grafts	365

(a)	Evidence of Autofacilitation in Some Cases of Allografted Endocrine Tissues	365
(b)	Active E-F of Ovarian Grafts	367
(c)	Passive E-F of Ovarian Grafts	367
(d)	Other Endocrine Tissue Grafts	367
3.	Kidney Allografts	368
(a)	Active E-F of Kidney Allografts	368
(b)	Passive E-F of Kidney Allografts	369
(c)	Association of Active and Passive E-F on Kidney Allograft Survival	369
4.	Other Tissues	369
(a)	Bones	370
(b)	Foeto-Placental Tissues	370
C.	Autoimmune Reactions and Diseases	371
1.	Ocular Structures	372
(a)	Experimental Phaco-Anaphylactic Endophthalmia	372
(b)	Experimental Sympathetic Ophthalmia	372
2.	Central Nervous System and Experimental Allergic Encephalomyelitis (EAE).	373
(a)	Active Facilitation in EAE	373
(b)	Inverse Relation between Occurrence of Lesions and Presence of Antibodies	373
(c)	Passive Facilitation in EAE	374
3.	Testis and Autoimmune Aspermatogenic Orchitis (AIAO)	374
(a)	Active Facilitation in AIAO	374
(b)	Passive Facilitation in AIAO	375
4.	Thyroid and Autoimmune Thyroiditis (AIT).	375
D.	Non-Tissue Antigens	375
1.	Erythrocytes	376
(a)	Passively Induced Phenomenon	376
(b)	Actively Induced Phenomenon	377
2.	Bacteria and Fungi	377
(a)	Clinical and Experimental Actinomycosis (Active E-F-like Phenomenon)	377
(b)	Passive E-F-Like Phenomenon with Bacterial Antigens	378
3.	Viruses	378
(a)	Depressive Action of Passive Antibody on Antibody Production	379
(b)	Depressive Action of Passive Antibody on Actively Induced Resistance to Infection	379
4.	Soluble Antigens	379
(a)	Passively Induced Phenomena	380
(b)	Actively Induced Phenomena	381
5.	Conclusions on E-F of Non-Tissue Antigens	382
E.	Conclusions of Section III	382
IV.	Mechanism of the Phenomenon	383
A.	Introduction	383

1.	Immune Cycle and Types of Reaction	383
(a)	The Primary Afferent Arc	383
(b)	The Central Reaction	383
(c)	The Efferent Arc	384
(d)	The Peripheral Reaction	384
(e)	The Anamnestic or Secondary Reaction	385
2.	Immune Mechanisms of Rejection	385
(a)	Immune Lymphoid Cells	385
(b)	The Role of Serum Antibodies	386
(c)	Possibility of Synergistic Action between Cells and Antibodies	387
3.	Complexity of the Mechanism of E-F	388
(a)	The Induction of E-F	388
(b)	The Role of the Target	389
B.	Mechanism of Passive E-F	389
1.	Theoretical Possibilities	389
2.	Experimental Evidence	391
(a)	Primary Antibody-Induced Modification of the Immune Response	391
(b)	Secondary Protection of Target by Specific Antibody (Immuno-protection)	396
3.	Conclusions on Mechanism of Passive E-F	401
C.	Mechanism of Active E-F	402
1.	Active E-F as the Counterpart of Passive E-F	402
2.	Suggestions of an Additional Mechanism	402
3.	Comparison of Active E-F with Immune Deviation	403
(a)	Immune Deviation	403
(b)	Active E-F	403
D.	Factors Depending on the Target Antigen and its Supporting Structures	404
1.	Antigens not Borne by Living Cells	405
2.	Antigens on Isolated Cells	405
3.	Normal Tissues <i>in situ</i>	405
4.	Homografted Tissues and Organs	407
5.	Tumors	407
E.	Conclusions of Section IV	408
V.	Responsible Antibodies	410
A.	Immunological Specificity and Corresponding Antigens	410
1.	Corresponding Antigens	410
2.	Mosaic of Monospecificities	410
3.	One-Determinant Specificity	410
4.	DH Specificity <i>versus</i> Antibody Specificity	410
B.	Avidity	411
1.	Hyperimmune Sera	411
2.	Measures of Avidity	411
C.	Nature (Biological Properties and Immunoglobulin Class)	411
1.	Theoretical Possibilities	411
(a)	The Purely Quantitative Concept	411

(b)	A Qualitative Concept	413
2.	Experimental Data	415
(a)	Relation to Other Antibody Properties	415
(b)	Immunoglobulin Class of E-F Antibodies	417
(c)	Part of the Immunoglobulin Responsible for E-F Activity (Fc <i>versus</i> Fab)	422
D.	Site of Formation of E-F Antibodies	425
1.	Role of the Spleen in the Production of E-F Antibodies Tested by Passive E-F Experiments	425
2.	Role of the Spleen in Active (Experimentally Induced) E-F	425
3.	Role of the Spleen in Active (Spontaneously Induced) E-F (Self- or Auto-E-F)	427
4.	Active Participation of Host Spleen in Passively Induced E-F	427
VI.	Place of the Enhancement-Facilitation Phenomenon in Immunobiology and Immunopathology	428
A.	Possible Roles in Immunobiology	428
1.	Regulation of the Immune Response	429
(a)	Regulation of Delayed Hypersensitivity	429
(b)	Regulation of 19S IgM Synthesis	429
(c)	Regulation of 7S IgG Synthesis	430
2.	Immunologic Tolerance	431
B.	Possible Role in Immunopathology	437
1.	Infectious Diseases	437
(a)	Protection of Multiplying Organisms	437
(b)	Desensitizing Action of E-F Antibodies	438
2.	Autoimmune Diseases	439
3.	Pregnancy	439
4.	Cancer	441
(a)	Role in Establishment or Development of Cancer	441
(b)	Predictable Consequences in Immunotherapy	442
5.	Recovery from Homologous Disease	443
(a)	Experimental Situation	443
(b)	Clinical Situation	445
6.	Organ Transplantation	446
	Acknowledgements	447
	References	447

Introduction

A. DE WECK

It is probably a platitude to state that we are presently experiencing a new golden age for immunology. Our understanding of cellular and humoral immunological reactions considerably increased during the last fifteen years and their importance in various fields of biology and medicine has become evident. The increasing significance of immunology in natural sciences and medicine is best demonstrated by the fact that immunologists shaking hands with laymen no longer have to go into lengthy explanations about the nature of their job, as was so often the case in the past.

Although the role of immunology and the relevance of allergic phenomena in the pathogenesis of various diseases were recognized by a number of pioneers already before World War II, it is one of the great merits of PAUL KALLÓS, the founder of this series more than 30 years ago to have given to allergy and clinical immunology some most fruitful impulses, the importance of which only now starts to be realized. In 1939 already [1], PAUL KALLÓS stated that 'only an intimate collaboration between basic and clinical research could really permit a progress in knowledge and the application of new results for the benefit of patients'. The concept that close contacts between theoretical biologists and medical practitioners are essential to progress in allergy has been one of the basic principles of the first Editor of this series and his guideline throughout his medical and scientific activities. The explosive development of basic immunology during the sixties is reflected by the increased pace of publication of new volumes of *Progress in Allergy*. At a time where the number of immunological journals and of original papers may no longer be encompassed even by the most voracious reader, review articles acquire a special significance and will frequently influence the thinking of immunologists for years to come.

The contribution of BYRON WAKSMANN, who joined PAUL KALLÓS as Editor in 1962, to the favorable development of this series and to its establishment as a collection of first class reviews in allergy and immunology cannot be overestimated.

Accordingly, it is not without some anguish that a junior Editor may envisage joining so successful elders and sharing with them what certainly amounts to a general responsibility towards the immunological community.

At the beginning of the seventies, allergy and immunology are entering in a new and probably very decisive period. Basic immunology has now become a branch of molecular and cell biology and, as recently stated in provocative terms by JERNE [2], its complete solution may be approaching. Never before have such concentrated efforts been undertaken in order to solve the remaining basic problems of immunology such as the types and functions of cells involved in immune responses, the genetic basis of antibody diversity, the molecular aspects of antibody production and secretion, the molecular characteristics responsible for various functions of antigens, the mechanisms responsible for regulation of antibody formation and the induction of the immune response. The considerable investments of universities and research agencies and the interest of the scientific community for basic immunology is documented in recent years by the foundation of Institutes of Immunology, of numerous national Societies of Immunology, of an International Union of Immunological Societies – which will hold its first Congress in Washington in 1971 – and also by the creation of several new immunological journals. However, for those interested in immunology not only as scientists, but as doctors, this evolution, however fruitful and necessary for a better understanding of human diseases, is not without presenting some problems. In order to ensure the rapid application of new immunological knowledge, proper channels of communications between basic immunologists and clinicians should be maintained and developed. The creation of units or departments of clinical immunology in universities and major hospitals will probably provide the basis for such exchanges and it is significant that after having recognized the importance of fostering basic immunology, the World Health Organization is now increasingly emphasizing clinical immunology.

With the all-encompassing significance and the prestige attached nowadays to the word immunology, it may be wondered whether allergy will be able to maintain much longer its broad original meaning implying a specific alteration of the capacity of the organism to react. From an etymological and historical point of view the fields covered by allergy and clinical immunology could be considered identical. On the other hand, it cannot be denied

that the rapid development of immunology on a broad front and its division in subspecialties such as immunohematology, immunological deficiencies, autoimmune diseases, transplantation and tumor immunology frequently had for consequence to isolate 'classical' allergists and to restrict them to the management of atopic diseases. However, there is a basic unity between all clinical aspects of immunology, namely the immunological apparatus itself, and its various modalities of action. The complaints of some traditional allergists about the ever increasing invasion of basic immunology in their professional journals and meetings are not compatible with progress in allergy, even if this term would be considered in its most restrictive clinical sense. At a time where a new generation of allergologists recognizes the importance of basic immunology in their daily lives and actively participates in the study of immunological phenomena, there appear to be no reasons to modify either the title or the orientation of this series. Progress in Allergy should remain a free means of communication and exchange between all kinds of immunologists and physicians. In some respects the concern expressed by PAUL KALLÓS and BYRON WAKSMANN in 1962 [3] appears somewhat prophetic and is still up to date: 'It is to be hoped that men coming from departments labeled 'Clinical Immunology' or 'Allergy and Infectious Diseases' will regard themselves as the allergists of the next medical era and will regard asthma, eczema, hay fever and urticaria as equal to systemic lupus erythematosus, rheumatoid arthritis, and Hashimoto's thyroiditis in their medical importance, on the one hand, and their interest as subjects for investigation, on the other. It would be a great misfortune were allergists and clinical immunologists to become separate categories of doctors'.

An important but still somewhat neglected field of allergy is the recognition and identification of molecular and chemical properties of clinically significant antigens and allergens. Reviews on house dust allergens [L. BERRENS, vol. 14], lipid antigens [M. M. RAPPORT and L. GRAF, vol. 13] insect allergens [S. SHULMAN, vol. 12] and protein antigens [M. KAMINSKI, vol. 9] have appeared in recent volumes. In this volume, G. SPRINGER reviews the antigenic determinants shared between lower forms of life – predominantly bacteria and viruses –, some human blood group antigens and a few related substances such as the so-called Forssmann antigens present on mammalian cell membranes, a subject of considerable immunological interest and clinical importance. Cross-reacting antigens and especially the chemical nature of the determinant substrates are peculiarly emphasized. Such cross-reactions may have a profound bearing on the immunological response of the host to